The evolving role of futibatinib for advanced cholangiocarcinoma
Futibatinib represents the most biologically rational FGFR inhibitor currently available for FGFR2-altered CCA, as it directly addresses the dominant mechanism limiting the efficacy of earlier agent, on-target resistance driven by secondary FGFR2 kinase domain mutations.
Authors
- Margherita Rimini
- Silvia Camera
- Mara Persano
- Andrea Casadei-Gardini
Institutions
- Vita-Salute San Raffaele University (IT)
- University of Cagliari (IT)
Publication Details
- Journal
- Expert Review of Gastroenterology & Hepatology
- Published
- 2026-03-23
- DOI
- https://doi.org/10.1080/17474124.2026.2649804
- Primary Topic
- Fibroblast Growth Factor Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00